Drug Trial Radar · NCT02636842
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
Last checked: Nov 20, 2026Latest source record: Jul 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Dec 2015
Primary completion
Jun 2016
Study completion Jun 2016
Sponsor
- Lead sponsor
- Alkermes, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 22, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will determine the safety, tolerability, and pharmacokinetics of aripiprazole lauroxil in adults with schizophrenia or schizoaffective disorder.
Conditions
- Schizophrenia
- Schizoaffective Disorder
Interventions
Aripiprazole LauroxilDrug
Intramuscular (IM) injection, single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum plasma concentration (Cmax)Time frame: Up to 7 days
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Alkermes Investigational Site
Cerritos, California
Alkermes Investigational Site
Lemon Grove, California
Alkermes Investigational Site
Oakland, California
Alkermes Investigational Site
Hoffman Estates, Illinois
Alkermes Investigational Site
Marlton, New Jersey
Alkermes Investigative Site
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.